ATOSSA THERAPEUTICS, INC. Deferred Tax Assets, Capital Loss Carryforwards
ATOSSA THERAPEUTICS, INC. (ATOS) had Deferred Tax Assets, Capital Loss Carryforwards of $1.03 million as of 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2020-03-26
- 2018-12-31: Deferred Tax Assets, Capital Loss Carryforwards $1.03M.
- 2017-12-31: Deferred Tax Assets, Capital Loss Carryforwards $1.03M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2018-12-31 | $1.03M 10-K · filed 2020-03-26 |
| 2017-12-31 | $1.03M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |